High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury
Minjun Chen, Jürgen Borlak, Weida Tong – 19 December 2012 – Drug‐induced liver injury (DILI) is a leading cause of drug failure in clinical trials and a major reason for drug withdrawals from the market. Although there is evidence that dosages of ≥100 mg/day are associated with increased risk for hepatotoxicity, many drugs are safe at such dosages. There is an unmet need to predict risk for DILI more reliably, and lipophilicity might be a contributing factor.